- Home
- CMLS vs SPRB Comparison
CMLS vs SPRB Comparison
Compare CMLS & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMLS
- SPRB
- Stock Information
- Founded
- CMLS 2002
- SPRB 2014
- Country
- CMLS United States
- SPRB United States
- Employees
- CMLS N/A
- SPRB N/A
- Industry
- CMLS Broadcasting
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- CMLS Consumer Discretionary
- SPRB Health Care
- Exchange
- CMLS Nasdaq
- SPRB Nasdaq
- Market Cap
- CMLS 14.5M
- SPRB 15.7M
- IPO Year
- CMLS 1998
- SPRB 2020
- Fundamental
- Price
- CMLS $0.88
- SPRB $0.42
- Analyst Decision
- CMLS Hold
- SPRB Hold
- Analyst Count
- CMLS 2
- SPRB 7
- Target Price
- CMLS N/A
- SPRB $2.17
- AVG Volume (30 Days)
- CMLS 27.1K
- SPRB 417.1K
- Earning Date
- CMLS 02-27-2025
- SPRB 03-12-2025
- Dividend Yield
- CMLS N/A
- SPRB N/A
- EPS Growth
- CMLS N/A
- SPRB N/A
- EPS
- CMLS N/A
- SPRB N/A
- Revenue
- CMLS $829,801,000.00
- SPRB $7,101,000.00
- Revenue This Year
- CMLS N/A
- SPRB N/A
- Revenue Next Year
- CMLS N/A
- SPRB N/A
- P/E Ratio
- CMLS N/A
- SPRB N/A
- Revenue Growth
- CMLS N/A
- SPRB N/A
- 52 Week Low
- CMLS $0.63
- SPRB $0.34
- 52 Week High
- CMLS $4.71
- SPRB $5.95
- Technical
- Relative Strength Index (RSI)
- CMLS 50.83
- SPRB 58.94
- Support Level
- CMLS $0.82
- SPRB $0.38
- Resistance Level
- CMLS $0.97
- SPRB $0.42
- Average True Range (ATR)
- CMLS 0.07
- SPRB 0.03
- MACD
- CMLS -0.00
- SPRB 0.00
- Stochastic Oscillator
- CMLS 48.19
- SPRB 69.77
About CMLS Cumulus Media Inc.
Cumulus Media Inc is an audio-first media company delivering content to over a quarter billion people every month wherever and whenever required. It is a radio broadcasting company combining high-quality local programming with iconic, nationally syndicated media, sports, and entertainment brands to deliver premium content choices to its customers and radio stations affiliated with Westwood One network and numerous digital channels. The company's revenue is derived mainly from the sale of local, regional, and national advertising which is broadcast on its radio stations.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).